4-Dimethylaminopyridine | CAS:1122-58-3

We serve 4-Dimethylaminopyridine CAS:1122-58-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Dimethylaminopyridine

Chemical Name:4-Dimethylaminopyridine
CAS.NO:1122-58-3
Synonyms:N-(4-Pyridyl)dimethylamine;DMAP
Molecular Formula:C7H10N2
Molecular Weight:122.16800
 
Physical and Chemical Properties:
Density:1.012;
Melting point:83-86oC;
Boiling point:211oC;
Flash point:110oC;
Index of Refraction:1.431;
 
HS Code: 2933399090
UN No.: UN2811
Hazard class: 8 categories 
Packing level: Class II
 
Specification:
Appearance:Off-white to white crystalline powder
Purity(HPLC):≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:As a condensation reagent



Contact us for information like 4-Dimethylaminopyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,DMAP physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(4-Pyridyl)dimethylamine Use and application,4-Dimethylaminopyridine technical grade,usp/ep/jp grade.


Related News: This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?2-Amino-4-fluorobenzoic acid manufacturer This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?Diethylcarbamyl chloride supplier Hong Kong confirmed its 14th coronavirus case late Saturday. The patient, an 80-year-old man, had traveled for a few hours to mainland China in early January, and later spent several days on a cruise ship in Japan with more than 3,000 passengers and employees.4-[(4-hydroxy-6-oxo-1H-pyrimidin-2-yl)amino]benzonitrile vendor Hong Kong confirmed its 14th coronavirus case late Saturday. The patient, an 80-year-old man, had traveled for a few hours to mainland China in early January, and later spent several days on a cruise ship in Japan with more than 3,000 passengers and employees.Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added.